Skip to search form
Skip to main content
Semantic Scholar's Logo
You are currently offline. Some features of the site may not work correctly.
National Institutes of Health
Semantic Scholar uses AI to extract papers important to this topic.
Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
Mukundan Baskar Mannargudi
Journal of Cancer Research and Clinical Oncology
Corpus ID: 1237456
PurposeRibonucleotide reductase (RR) enzymes (RR1 and RR2) play an important role in the reduction of ribonucleotides to…
GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors.
Aiping H. Young
International journal of oncology
Corpus ID: 30751090
GTI-2501 is a 20-mer oligonucleotide that is complementary to a coding region in the mRNA of R1, the large subunit of…
Dose escalation phase of a phase I/II study of GTI-2501, an antisense to the R1 subunit of ribonucleotide reductase (RNR) and docetaxel in patients with metastatic hormone-refractory prostate cancer.
Journal of clinical oncology : official journal…
Corpus ID: 37144681
2078 Background: GTI-2501 (GTI) is a 20-mer oligonucleotide that is complementary to the R1 subunit of the RNR mRNA. The R1…
GTI-2501. Lorus Therapeutics.
Current opinion in investigational drugs
Corpus ID: 52312
Lorus Therapeutics (formerly GeneSense Technologies) is developing GTI-2501, directed against the R1 component of ribonucleotide…
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Terms of Service
ACCEPT & CONTINUE